Skip to content
Clinical Trials – home

Danderyds Sjukhus AB

Verifiedinfo

Sweden Morbygardsvagen 88, 182 88 Danderyd, Sweden

  • 29 trials recruiting
  • Atrial fibrillation · Chronic kidney disease · Hypertension
  • Adults and children

About Specializations

Danderyds Sjukhus AB in Danderyd, Sweden specialises in clinical trials of conditions such as Atrial fibrillation, Chronic kidney disease, Hypertension, Crohn's disease, and other specialisations. This site conducts important research.

Main research areas of the site

Renal & Immune‑Mediated Disorders

The department focuses on immune‑mediated kidney diseases such as IgA nephropathy, C3 glomerulopathy, focal segmental glomerulosclerosis and related proteinuric conditions, aiming to test new agents that preserve renal function and lower protein loss.

  • Strategies to reduce proteinuria
  • Complement pathway inhibition
  • Oral therapies for chronic kidney disease progression

Danderyds Sjukhus AB supports over 50 active studies with 40 investigators, reflecting a strong commitment to advancing renal health.

Cardiovascular & Heart Failure Research

Investigations target major cardiovascular conditions including heart failure with preserved or reduced ejection fraction, atrial fibrillation, acute myocardial infarction and resistant hypertension, evaluating novel drugs and combination regimens to lower mortality and hospitalisation.

  • SGLT2 inhibitor‑based combination therapies
  • New oral agents for blood pressure control
  • Anticoagulation alternatives for patients unsuitable for standard therapy

The site’s multidisciplinary team collaborates across cardiology and nephrology to improve outcomes for high‑risk patients.

Inflammatory Bowel Disease

Clinical work in Crohn’s disease and ulcerative colitis explores biologic and small‑molecule treatments designed to achieve clinical remission, endoscopic healing, and long‑term disease control.

  • Maintenance therapy optimization
  • Endoscopic response as a trial endpoint
  • Combination of vedolizumab with upadacitinib

Research also includes primary sclerosing cholangitis, linking liver and gut inflammation in a comprehensive IBD program.

Infectious Disease Research

The unit conducts studies on viral and bacterial threats such as COVID‑19, chronic hepatitis D, tick‑borne encephalitis and severe viral lung infections, testing antivirals, immunoglobulin adjuncts and vaccine‑related outcomes.

  • Antiviral efficacy and safety
  • Immunoglobulin therapy for immunocompromised hosts
  • Biomarker‑driven assessment of viral injury

These trials contribute to global efforts to improve infectious disease management and preparedness.

Orthopedic & Surgical Infection Prevention

Research on prosthetic joint infection and hip arthroplasty evaluates antibiotic‑impregnated bone grafts and analgesic techniques to reduce postoperative infection rates and enhance recovery.

  • Bone graft infection control strategies
  • Comparison of intrathecal morphine vs epidural analgesia
  • Patient‑reported recovery quality after colorectal surgery

The surgical team integrates infection‑prevention science with modern operative practice.

Women’s Health & Reproductive Medicine

Studies address contraception after medical abortion, management of vulvovaginal atrophy, and the neurological impact of hormonal contraceptives, seeking safer, more effective options for women’s reproductive health.

  • Immediate intrauterine device insertion post‑abortion
  • Selective estrogen receptor modulators for atrophy symptoms
  • Brain structure and function effects of combined hormonal contraceptives

The department collaborates with obstetrics and endocrinology to optimize women's health outcomes.

Critical Care & Neurology

The Intensive Care Platform Trial (INCEPT) and stroke studies examine acute interventions for acute ischemic stroke and severe viral encephalitis, comparing early thrombolysis strategies and measuring neuronal injury biomarkers.

  • Early thrombolysis in patients on factor Xa inhibitors
  • Platform trial design for ICU interventions
  • Neurofilament light chain as a marker of viral brain injury

These efforts aim to standardize care and improve survival in critically ill patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Morbygardsvagen 88182 88 DanderydSweden
Recruiting now
29 trials
Conditions studied
55
Partner status
Verified

More sites in DanderydSweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

65 clinical trials

Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB

Renal disorder

Recruiting
Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting
Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB
Countries:SwedenSweden
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.